MabVax Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MabVax Therapeutics, Inc.
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.
Scientists at NEO New Oncology AG and the University of Cologne have identified previously unknown genomic alterations in neuroblastoma which may help improve tumor diagnostics and potentially leading to the development of new therapies for the pediatric disease.
MabVax to provide antibody-targeting technology to Memorial Sloan-Kettering, which could yield CAR-T therapeutic candidates for which Juno Therapeutics will hold an exclusive option. Mylan acquires injectable anticoagulant Arixtra from Aspen for $300 million, while Asterias will work with Cancer Research UK on non-small cell lung cancer program.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.